At 2mg five times weekly, 100mg lasts about 10 weeks, covering most protocols
Unless there is clear evidence of primary bladder pathology (e.g., small capacity under anesthesia, Hunner lesions), patients should have a multidisciplinary evaluation including assessment for neuropathic pain and psychological profile
Among the list of Major Modifications for 2025 is that guanfacine has been clarified not to be a prohibited substance
Safety Considerations and Monitoring Peptide therapy for sperm quality improvement maintains an excellent safety profile when properly administered and monitored
While no medical treatment is completely without risk, receiving care within a clinical environment provides safeguards that simply arent available when individuals attempt to self-manage peptide therapy
Known peptide or copper hypersensitivity obvious but worth stating